Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-13

Clinical Trial Update: Neoadjuvant BKM120 in High-risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating BKM120 in high-risk prostate cancer was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BKM120 (Buparlisib)

Snippet

Sponsor: Won Kim | Conditions: High Risk Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-01-13